Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

PaperCitations, authors & open-access status

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 82 citations, 2023 year and bronze oa status.

82
Citations
2023
Year
bronze
OA Status

Related on ScholarIQ

Vincent Verschaeve
Author
Annals of Oncology
Journal
Bladder and Urothelial Cancer Treatments
Topic
Bladder and Urothelial Cancer Treatments
Topic
Fibroblast Growth Factor Research
Topic
Urinary and Genital Oncology Studies
Topic
470M+ articles · free account